RxDoctor Payments Data

Maria Colta

Nurse Practitioner · Arlington Heights, ILNPI 1912662651

Payments from drug & device makers

$5,444in general payments, 2019–2025

Across 209 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$811
  • Novartis$634
  • Merck$529
  • AbbVie$340
  • Lilly USA, LLC$253
  • Gilead$234
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,26097%
  • Education$1843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,444 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$118,839
Medicare patients
244
Services billed
2,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide34$521,558
BrukinsaZanubrutinib30$448,865
JakafiRuxolitinib Phosphate19$353,558
OrserduElacestrant Hcl12$260,340
TagrissoOsimertinib Mesylate14$247,330
CalquenceAcalabrutinib Maleate15$231,088
EliquisApixaban220$191,133
Abiraterone Acetate20$129,023
XareltoRivaroxaban62$60,846
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen81$1,727
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$704
Potassium Chloride54$517
Prochlorperazine Maleate58$516
Morphine Sulfate ErMorphine Sulfate22$486
Warfarin Sodium38$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$201$582,40496 claims
AstraZenecaTagrisso, Calquence$811$478,41829 claims
Beigene USA, Inc.Brukinsa$70$448,86530 claims
Incyte CorporationJakafi$199$353,55819 claims
PfizerEliquis$134$191,133220 claims
Lilly USA, LLCOlanzapine$253$42223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →